Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-zzh7m Total loading time: 0 Render date: 2024-04-27T21:44:03.960Z Has data issue: false hasContentIssue false

10 - Prioritizing the Components of Any Decision-Making Model

Published online by Cambridge University Press:  25 March 2024

Joseph F. Goldberg
Affiliation:
Icahn School of Medicine at Mount Sinai, New York
Stephen M. Stahl
Affiliation:
University of California San Diego
Get access

Summary

If we had to pick the single most important factor that goes into clinical decision-making in psychiatry, it would not be anything related to pharmacology, psychotherapy, genetics, Maudsley staging scores, or any other kinds of historical illness characteristics, but rather, it would be determining the appropriate level of care needed for a given individual patient. Why is that, given the many breakthroughs in neuroscience and our understanding of psychopharmacology? Nobel prizes have been awarded for elucidating the intricacies of second messenger signal transduction in neurons, but not for the intricacies of deducing the merits of an intensive outpatient program versus a partial hospital program. Or for knowing when a multidisciplinary “team” approach is wiser than being seen by an individual practitioner. For all the attention heaped upon presumptive brain mechanisms of psychopathology and the impact of evidence-based treatments thought to modulate brain dysfunction, one cannot escape the psychosocial context in which most mental health conditions arise. Chronic and recurrent mental health conditions often spill into people’s daily lives in ways that can be tumultuous, volatile, and precarious. Coping with distress and adversity often can become a primary goal of treatment, and for some difficult-to-treat psychiatric conditions, questing for a medicine to eradicate chronic symptoms may sometimes need relegation to a secondary rather than primary objective. Many treatments in psychiatry are more disease-managing than disease-modifying (meaning, they may lessen the adverse impact of psychiatric symptoms but not necessarily eradicate or prevent them).

Type
Chapter
Information
Publisher: Cambridge University Press
Print publication year: 2024

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000Google Scholar
Barbosa, L, Berk, M, Voster, M.A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 2003; 64: 403407CrossRefGoogle ScholarPubMed
Berwaerts, J, Xu, H, Nuamah, I, et al.Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: A randomized, double-blind, dose-response study. J Affect Disord 2012a; 136 (1–2): e51e60CrossRefGoogle Scholar
Berwaerts, J, Melkote, R, Nuamah, I, et al.A randomized, placebo- and active-controlled study of paliperidone extended-release as maintenance treatment in patients with bipolar I disorder after an acute manic or mixed episode. J Affect Disord 2012b; 138: 247258CrossRefGoogle ScholarPubMed
Bowden, CL, Calabrese, JR, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392400CrossRefGoogle ScholarPubMed
Bowden, CL, Vieta, E, Ice, KS, et al.Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: A 6-month, randomized, placebo-controlled, double-blind trial. J Clin Psychiatry 2010; 71: 130137CrossRefGoogle Scholar
Calabrese, JR, Bowden, CL, Sachs, G, et al.A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 10131024CrossRefGoogle ScholarPubMed
Calabrese, JR, Pikalov, A, Streicher, C, et al.Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol 2017a; 27: 865876CrossRefGoogle ScholarPubMed
Calabrese, JR, Sanchez, R, Jin, N, et al.Efficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: A double-blind, placebo-controlled, 52-week randomized withdrawal study. J Clin Psychiatry 2017b; 78: 324331CrossRefGoogle ScholarPubMed
Calabrese, JR, Durgam, S, Satlin, A, et al.Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo- controlled trial. Am J Psychiatry 2021; 178: 10981106CrossRefGoogle ScholarPubMed
Chengappa, KNR, Baker, RW, Shao, L, et al.Rates of response, euthymia and remission in two placebo-controlled olanzapine trials for bipolar mania. Bipolar Disord 2003; 5: 15CrossRefGoogle ScholarPubMed
Dunner, DL, Fieve, RR.Clinical factors in lithium carbonate prophylaxis failure. Arch Gen Psychiatry 1974; 30: 229233CrossRefGoogle ScholarPubMed
Durgam, S, Earley, W, Lipschitz, A, et al.An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry 2016a; 173: 271281CrossRefGoogle ScholarPubMed
Durgam, S, Earley, W, Guo, H, et al.Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: A randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry 2016b; 77: 371378CrossRefGoogle ScholarPubMed
Earley, W, Durgam, S, Lu, K, et al.Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies. J Affect Disord 2017; 215: 205212CrossRefGoogle Scholar
Earley, W, Burgess, MV, Rekeda, L, et al.Cariprazine treatment of bipolar depression: A randomized double-blind placebo-controlled phase 3 study. Am J Psychiatry 2019; 176: 439448CrossRefGoogle ScholarPubMed
Earley, WR, Burgess, MV, Khan, B, et al.Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study. Bipolar Disord 2020; 22: 372384CrossRefGoogle ScholarPubMed
Frank, E, Prien, RF, Jarrett, RB, et al.Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48: 851855CrossRefGoogle ScholarPubMed
Friedlander, ML, Austin, CL, Cabrera, P.When psychotherapy is indefinite and there is no final outcome: Case study of a community mental health clinic. Psychotherapy (Chic) 2014; 51: 580594CrossRefGoogle ScholarPubMed
Geddes, JR, Gardiner, A, Rendell, J, et al.Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: A randomised, open-label, pilot study. Lancet Psychiatry 2016; 3: 3139CrossRefGoogle Scholar
Gelenberg, AJ, Kane, JM, Keller, MB, et al.Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med 1989; 321: 14891493CrossRefGoogle ScholarPubMed
Goldberg, JF, Stahl, SM.Practical Psychopharmacology: Translating Findings from Evidence-Based Trials into Real-World Clinical Practice. Cambridge: Cambridge University Press, 2021CrossRefGoogle Scholar
Grof, P, Duffy, A, Cavazzoni, P, et al.Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002; 62: 942947CrossRefGoogle Scholar
Høglend, P, Sørbye, Ø, Sørlie, T, et al.Selection criteria for brief dynamic psychotherapy: Reliability, factor structure and long-term predictive value. Psychother Psychosom 1992; 57: 6774Google Scholar
Joyce, AS, Piper, WE, Ogrodniczuk, JS, et al.Termination in Psychotherapy: A Psychodynamic Model of Processes and Outcomes. Washington, DC: American Psychological Association, 2007CrossRefGoogle Scholar
Kayser, A, Robinson, DS, Nies, A, et al.Response to phenelzine among depressed patients with features of hysteroid dysphoria. Am J Psychiatry 1985; 142: 486488Google ScholarPubMed
Keck, PE Jr., Marcus, R, Tourkodimitris, S, et al.A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003; 160: 16511658CrossRefGoogle ScholarPubMed
Keck, PE Jr., Calabrese, JR, McIntyre, RS, et al.Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: A 100-week, double-blind study versus placebo. J Clin Psychiatry 2008; 68: 14801491CrossRefGoogle Scholar
Keck, PE Jr., Orsulak, PJ, Cutler, AJ, et al.Aripiprazole monotherapy in the treatment of acute bipolar I mania: A randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009; 112 (1–3): 3649CrossRefGoogle Scholar
Kishi, T, Ikuta, T, Sakuma, K, et al.Comparison of quetiapine immediate- and extended-release formulations for bipolar depression: A systematic review and network meta-analysis of double-blind, randomized placebo-controlled trials. J Psychiatr Res 2019; 115: 121128CrossRefGoogle ScholarPubMed
Klein, DF, Liebowitz, MR.Hysteroid dysphoria. Am J Psychiatry 1982; 139: 15201521Google ScholarPubMed
Kushner, SF, Khan, A, Lane, R, et al.Topiramate monotherapy in the management of acute mania: Results of four double-blind placebo-controlled trials. Bipolar Disord 2006; 8: 1527CrossRefGoogle ScholarPubMed
Landbloom, RL, Mackle, M, Wu, X, et al.Asenapine: efficacy and safety of 5 and 10mg bid in a 3-week, randomized, double-blind, placebo-controlled trial in adults with a manic or mixed episode associated with bipolar I disorder. J Affect Disord 2016; 190: 103110CrossRefGoogle ScholarPubMed
Loebel, A, Cucchiaro, J, Silva, R, et al.Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014a; 171: 160168CrossRefGoogle ScholarPubMed
Loebel, A, Cucchiaro, J, Silva, R, et al.Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. Am J Psychiatry 2014b; 171: 169177CrossRefGoogle ScholarPubMed
Lombardo, I, Sachs, G, Kolluri, S, et al.Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: Did baseline characteristics impact trial outcome? J Clin Psychopharmacol 2012; 32: 470478CrossRefGoogle ScholarPubMed
Maas Genannt Bermpohl, F, Hülsmann, L, Martin, A.Efficacy of mindfulness- and acceptance-based cognitive–behavioral therapies for bodily distress in adults: A meta-analysis. Front Psychiatry 2023; 14: 1160908CrossRefGoogle ScholarPubMed
Maina, G, Albert, U, Rosso, G, et al.Olanzapine or lamotrigine addition to lithium in remitted bipolar disorder patients with anxiety disorder comorbidity: A randomized, single-blind, pilot study. J Clin Psychiatry 2008; 69: 609616CrossRefGoogle ScholarPubMed
Maneeton, N, Maneeton, B, Srisurapanont, M, et al.Quetiapine monotherapy in acute phase for major depressive disorder: A meta-analysis of randomized, placebo-controlled trials. BMC Psychiatry 2012; 12: 160CrossRefGoogle ScholarPubMed
Maneeton, N, Maneeton, B, Woottiluk, P, et al.Quetiapine monotherapy in acute treatment of generalized anxiety disorder: A systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2016; 10: 259276CrossRefGoogle ScholarPubMed
McElroy, SL, Weisler, RH, Chang, W, et al.A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar I depression (EMBOLDEN II). J Clin Psychiatry 2010; 71: 163174CrossRefGoogle ScholarPubMed
McIntyre, RS, Cohen, M, Zhao, J, et al.A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord 2009; 11: 673686CrossRefGoogle ScholarPubMed
McIntyre, RS, Cohen, M, Zhao, J, et al.Asenapine in the treatment of acute mania in bipolar I disorder: A randomized, double-blind, placebo-controlled trial. J Affect Disord 2010; 122 (1–2): 2738CrossRefGoogle ScholarPubMed
McIntyre, RS, Cucchiaro, J, Pikalov, A, et al.Lurasidone in the treatment of bipolar depression with mixed (subsyndromal hypomanic) features: Post hoc analysis of a randomized placebo-controlled trial. J Clin Psychiatry 2015; 76: 398–205CrossRefGoogle ScholarPubMed
McIntyre, RS, Durgam, S, Huo, J, et al.The efficacy of lumateperone in patients with bipolar depression with mixed features. J Clin Psychiatry 2023; 84(3): 22m14739CrossRefGoogle ScholarPubMed
Nemeroff, CB, Evans, DL, Gyulai, L, et al.Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001; 158: 906912CrossRefGoogle ScholarPubMed
Owenby, RK, Brown, LT, Brown, JN.Use of risperidone as augmentation treatment for major depressive disorder. Ann Pharmacother 2011; 45: 95100CrossRefGoogle ScholarPubMed
Pande, AC, Crockatt, JG, Janney, CA, et al.Gabapentin in bipolar disorder: A placebo-controlled trial of adjunctive therapy. Gabapentin Bipolar Disorder Study Group. Bipolar Disord 2000; 2: 249255CrossRefGoogle ScholarPubMed
Papakostas, GI, Fava, M, Baer, L, et al.Ziprasidone augmentation of escitalopram for major depressive disorder: Efficacy results from a randomized, double-blind, placebo-controlled study. Am J Psychiatry 2015; 172: 12511258CrossRefGoogle ScholarPubMed
Quiroz, JA, Yatham, LN, Palumbo, JM, et al.Risperidone long-acting injectable monotherapy in the maintenance treatment of bipolar I disorder. Biol Psychiatry 2010; 68: 156162CrossRefGoogle ScholarPubMed
Rendell, JM, Gijsman, HS, Bauer, MS, et al.Risperidone alone or in combination for acute mania. Cochrane Database Syst Rev 2006; 1: CD004043Google Scholar
Roth, A, Fonagy, P.What Works for Whom?, 2nd edition. New York: Guilford Press, 2005Google Scholar
Rush, AJ, Kraemer, H, Sackeim, HA, et al.Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31: 18411853CrossRefGoogle ScholarPubMed
Sachs, GS, Nierenberg, AA, Calabrese, JR, et al.Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007; 356: 17111722CrossRefGoogle ScholarPubMed
Sachs, GS, Yeung, PP, Rekeda, L, et al.Adjunctive cariprazine for the treatment of patients with major depressive disorder: A randomized, double-blind, placebo-controlled phase 3 study. Am J Psychiatry 2023; 180: 241251CrossRefGoogle ScholarPubMed
Salloum, IM, Cornelius, JR, Daley, DC, et al.Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: A double-blind placebo-controlled study. Arch Gen Psychiatry 2005; 62: 3745CrossRefGoogle ScholarPubMed
Scott, J, Bellivier, F, Manchia, M, et al.Can network analysis shed light on predictors of lithium response in bipolar I disorder? Acta Psychiatr Scand 2020; 141: 522533CrossRefGoogle ScholarPubMed
Shinfuku, M, Kishimoto, T, Uchida, H, et al.Effectiveness and safety of long-term benzodiazepine use in anxiety disorders: A systematic review and meta-analysis. Int Clin Psychopharmacol 2019; 34: 211221CrossRefGoogle ScholarPubMed
Sifneos, P.Short-term Dynamic Psychotherapy. New York: Plenum, 1979CrossRefGoogle Scholar
Suppes, T, Vieta, E, Gustafsson, U, et al.Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: Analysis of two large randomized, placebo-controlled trials. Depress Anxiety 2013; 30: 10891098CrossRefGoogle ScholarPubMed
Swann, AC, Bowden, CL, Morris, D, et al.Depression during mania. Treatment response to lithium or divalproex. Arch Gen Psychiatry 1997; 54: 3742CrossRefGoogle ScholarPubMed
Swann, AC, Bowden, CL, Calabrese, JR, et al.Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am J Psychiatry 1999; 156: 1264-1266CrossRefGoogle ScholarPubMed
Szegedi, A, Durgam, S, Mackle, M, et al.Randomized, double-blind, placebo-controlled trial of asenapine maintenance therapy in adults with an acute manic or mixed episode associated with bipolar I disorder. Am J Psychiatry 2018; 175: 7179CrossRefGoogle ScholarPubMed
Thase, ME, Jonas, A, Khan, A, et al.Aripiprazole monotherapy in nonpsychotic bipolar I depression: Results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008a; 28: 1320CrossRefGoogle ScholarPubMed
Thase, ME, Trivedi, MH, Nelson, JC, et al.Examining the efficacy of adjunctive aripiprazole in major depressive disorder: A pooled analysis of 2 studies. Prim Care Compan J Clin Psychiatry 2008b; 10: 440447CrossRefGoogle Scholar
Thase, ME, Zhang, P, Weiss, C, et al.Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: Overview of four short-term studies. Expert Opin Pharmacother 2019; 20: 19071916CrossRefGoogle ScholarPubMed
Tohen, M, Goldberg, JF, Gonzalez-Pinto Arrillaga, AM, et al.A 12-week, double blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003; 60: 1218-1226CrossRefGoogle ScholarPubMed
Tohen, M, Greil, W, Calabrese, JR, et al.Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005; 162: 12811290CrossRefGoogle ScholarPubMed
Tohen, M, Calabrese, JR, Sachs, GS, et al.Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry 2006; 163: 247256CrossRefGoogle ScholarPubMed
Tohen, M, Case, M, Trivedi, MH, et al.Olanzapine/fluoxetine combination in patients with treatment-resistant depression: Rapid onset of therapeutic response and its predictive value for subsequent overall response in a pooled analysis of 5 studies. J Clin Psychiatry 2010; 71: 451462CrossRefGoogle Scholar
Tohen, M, Katagiri, H, Fujikoshi, S, et al.Efficacy of olanzapine monotherapy in acute bipolar depression: A pooled analysis of controlled studies. J Affect Disord 2013; 149 (1–3): 196201CrossRefGoogle ScholarPubMed
van der Loos, ML, Mulder, PG, Hartong, EG, et al.Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: A multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 223231CrossRefGoogle ScholarPubMed
Vieta, E, Goikolea, JM, Martínez-Arán, A, et al.A double-blind, randomized, placebo-controlled, prophylaxis study of adjunctive gabapentin for bipolar disorder. J Clin Psychiatry 2006; 67: 473477CrossRefGoogle ScholarPubMed
Vieta, E, Goldberg, JF, Mullen, J, et al.Quetiapine in the treatment of acute mania: Target dose for efficacious treatment. J Affect Disord 2007; 100 (suppl 1): S23S31CrossRefGoogle ScholarPubMed
Vieta, E, Nuamah, IF, Lim, P, et al.A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord 2010; 12: 230243CrossRefGoogle ScholarPubMed
Vieta, E, Montgomery, S, Sulaiman, AH, et al.A randomized, double-blind, placebo-controlled trial to assess prevention of mood episodes with risperidone long-acting injectable in patients with bipolar I disorder. Eur Neuropsychopharmacol 2012; 22: 825835CrossRefGoogle ScholarPubMed
Vieta, E, Sachs, G, Chang, D, et al.Two randomized, double-blind, placebo-controlled trials and one open-label, long-term trial of brexpiprazole for the acute treatment of bipolar mania. J Psychopharmacol 2021; 35: 971982CrossRefGoogle ScholarPubMed
Villarreal, G, Hamner, MB, Cañive, JM, et al.Efficacy of quetiapine monotherapy in posttraumatic stress disorder: A randomized, placebo-controlled trial. Am J Psychiatry 2016; 173: 12051212CrossRefGoogle ScholarPubMed
Yatham, LN, Mackala, S, Basivireddy, J, et al.Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: A randomised, open-label, pilot study. Lancet Psychiatry 2017; 4: 208217CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×